Stock ASND ASCENDIS PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ascendis Pharma A/S

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
130.4 USD +0.75% Intraday chart for Ascendis Pharma A/S +6.20% +3.54%
May. 22 European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
May. 16 Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,924 7,375 6,716 6,376 6,455 6,839 - -
Enterprise Value (EV) 1 5,326 6,748 6,138 6,149 6,601 7,408 7,115 6,622
P/E ratio -26.5 x -16.5 x -16.9 x -11 x -13.3 x -24.8 x 2,483 x 22.7 x
Yield - - - - - - - -
Capitalization / Revenue 443 x 1,061 x 863 x 125 x 24.2 x 15.4 x 9.4 x 5.79 x
EV / Revenue 398 x 970 x 789 x 120 x 24.7 x 16.7 x 9.78 x 5.61 x
EV / EBITDA -24.2 x -21 x -14.1 x -11.3 x -15.1 x -38.8 x -555 x 29.1 x
EV / FCF -28 x -23.2 x -13.9 x -12.1 x -14.1 x -46.7 x 119 x 33.1 x
FCF Yield -3.57% -4.32% -7.19% -8.3% -7.12% -2.14% 0.84% 3.02%
Price to Book 9.97 x 8.24 x 7.33 x 24.3 x -44.1 x 707 x 24.8 x 15.2 x
Nbr of stocks (in thousands) 47,740 54,006 56,755 55,872 56,568 57,345 - -
Reference price 2 124.1 136.6 118.3 114.1 114.1 120.1 120.1 120.1
Announcement Date 4/1/20 3/10/21 3/2/22 2/16/23 2/7/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 13.38 6.953 7.778 51.17 266.7 443.9 727.2 1,181
EBITDA 1 -220 -321.2 -436.4 -543.9 -436.6 -190.8 -12.82 227.4
EBIT 1 -226.7 -330.6 -451.8 -561.8 -455.5 -192.2 14.95 348.3
Operating Margin -1,695.1% -4,755.07% -5,808.59% -1,097.85% -170.79% -43.3% 2.06% 29.49%
Earnings before Tax (EBT) 1 -218.2 -419.2 -383.9 -577.8 -474.1 -265.8 9.635 362.2
Net income 1 -218 -419 -383.6 -583.2 -481.4 -281.4 8.118 319.4
Net margin -1,630.03% -6,025.53% -4,931.56% -1,139.63% -180.51% -63.4% 1.12% 27.04%
EPS 2 -4.690 -8.280 -7.000 -10.40 -8.550 -4.844 0.0484 5.304
Free Cash Flow 1 -190.2 -291.4 -441.4 -510.2 -469.8 -158.8 59.87 199.9
FCF margin -1,421.72% -4,191.11% -5,674.38% -996.97% -176.14% -35.78% 8.23% 16.92%
FCF Conversion (EBITDA) - - - - - - - 87.9%
FCF Conversion (Net income) - - - - - - 737.43% 62.58%
Dividend per Share 2 - - - - - - - -
Announcement Date 4/1/20 3/10/21 3/2/22 2/16/23 2/7/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4.897 6.828 6.16 15.29 22.9 33.59 47.39 48.03 137.7 95.89 88.02 110.8 147 169.1 190.4
EBITDA 1 -108.3 -123.6 -137.5 -140 - -139.1 - -129.7 -31.63 -44.67 -51.12 -41.16 -30.03 - -
EBIT 1 -112.6 -128 -141.9 -144.5 -147.4 -143.7 -140.8 -134.4 -36.61 -49.14 -67.76 -50.03 -22.08 -12.07 1
Operating Margin -2,298.98% -1,875.06% -2,303.46% -945.09% -643.72% -427.77% -297.17% -279.82% -26.59% -51.25% -76.98% -45.17% -15.02% -7.14% 0.53%
Earnings before Tax (EBT) 1 -106.2 -125.3 -81.37 -169.1 -202.1 -109.6 -121.9 -161.6 -81.09 -128.5 -68.2 -49.05 -22.73 8 9
Net income 1 -106.1 -125.5 -81.32 -169 -207.4 -110.9 -121.4 -162.2 -86.88 -131 -73.2 -55.87 -25.18 8 7
Net margin -2,165.86% -1,837.99% -1,320.11% -1,105% -905.91% -330.21% -256.23% -337.73% -63.09% -136.65% -83.16% -50.43% -17.13% 4.73% 3.68%
EPS 2 -1.870 -2.210 -1.460 -3.030 -3.700 -1.980 -2.160 -2.880 -1.540 -2.300 -1.270 -0.9663 -0.4345 0.1500 0.1300
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 3/2/22 5/11/22 8/10/22 11/2/22 2/16/23 4/27/23 9/5/23 11/7/23 2/7/24 5/2/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 146 570 277 -
Net Cash position 1 598 627 577 227 - - - 216
Leverage (Debt/EBITDA) - - - - -0.3345 x -2.986 x -21.59 x -
Free Cash Flow 1 -190 -291 -441 -510 -470 -159 59.9 200
ROE (net income / shareholders' equity) -49.7% -58.4% -44.5% -102% -818% - -110% 116%
ROA (Net income/ Total Assets) -43.8% -50.6% -37.2% - -50.3% -31.3% 13.7% 39.5%
Assets 1 497.8 828.3 1,032 - 957.7 899.6 59.06 807.8
Book Value Per Share 2 12.40 16.60 16.10 4.700 -2.590 0.1700 4.850 7.880
Cash Flow per Share 2 -3.980 -5.360 -7.630 -8.840 -8.300 -3.430 0.8000 -
Capex 1 5.16 19.9 23.7 14.5 2.44 7.17 6 4.2
Capex / Sales 38.57% 285.63% 304.76% 28.31% 0.92% 1.61% 0.83% 0.36%
Announcement Date 4/1/20 3/10/21 3/2/22 2/16/23 2/7/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Ascendis Pharma A/S

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
120.1 EUR
Average target price
168.3 EUR
Spread / Average Target
+40.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ASCENDIS PHARMA A/S Stock Ascendis Pharma A/S
+3.54% 7.42B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 116B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.89B
ARGENX SE Stock argenx SE
-1.69% 21.58B
GENMAB A/S Stock Genmab A/S
-10.60% 18.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.96B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 16.33B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 12.02B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ASND Stock
  4. Financials Ascendis Pharma A/S